Roquette has purchased a majority stake in excipient manufacturer Crest Cellose, in an aim to increase its footprint in India’s generic pharmaceutical market.
Cultural differences and broken promises are behind Indian GMP failures and acute generics shortages in the UK, according to one pharmaceutical distributor.
Sandoz, the generics subsidiary of Swiss pharmaceutical company
Novartis, is rumoured to be planning an acquisition in India in a
move that would give it back the top slot in the sector.
Last year, pharmaceutical companies from India submitted a third of
all the Drug Master Files for active pharma ingredients (APIs)
received in the US, outstripping their international rivals by a
wide margin.